Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.

Schneider F, Erisson L, Beygi H, Bradbury M, Cohen-Barak O, Grachev ID, Guzy S, Loupe PS, Levi M, McDonald M, Savola JM, Papapetropoulos S, Tracewell WG, Velinova M, Spiegelstein O.

Br J Clin Pharmacol. 2018 Oct;84(10):2422-2432. doi: 10.1111/bcp.13702. Epub 2018 Aug 9.

2.

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.

Bond M, Schoedel KA, Rabinovich-Guilatt L, Gasior M, Tracewell W, Malamut R, Ma Y, Webster LR.

Pain Med. 2018 Aug 1;19(8):1597-1612. doi: 10.1093/pm/pnx133.

3.

Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.

Bond M, Rabinovich-Guilatt L, Selim S, Darwish M, Tracewell W, Robertson P Jr, Yang R, Malamut R, Colucci P, Ducharme MP, Spiegelstein O.

Clin Drug Investig. 2017 Dec;37(12):1153-1163. doi: 10.1007/s40261-017-0575-3.

PMID:
28948482
4.
5.

Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology.

Darwish M, Yang R, Tracewell W, Robertson P Jr, Bond M.

Clin Pharmacol Drug Dev. 2016 Mar;5(2):141-9. doi: 10.1002/cpdd.238. Epub 2016 Jan 19.

PMID:
27138027
6.

Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA(®) Abuse Deterrence Technology.

Darwish M, Bond M, Yang R, Tracewell W, Robertson P Jr.

Clin Drug Investig. 2015 Oct;35(10):645-52. doi: 10.1007/s40261-015-0324-4.

7.

Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology.

Darwish M, Yang R, Tracewell W, Robertson P Jr, Bond M.

Clin Drug Investig. 2015 May;35(5):291-7. doi: 10.1007/s40261-015-0280-z.

PMID:
25813216
8.

Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.

Darwish M, Yang R, Tracewell W, Robertson P Jr, Bond M.

Clin Ther. 2015 Feb 1;37(2):390-401. doi: 10.1016/j.clinthera.2014.11.014. Epub 2014 Dec 24.

PMID:
25542074
9.
10.

Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.

Marley K, Helfand SC, Simpson J, Mata JE, Tracewell WG, Brownlee L, Bracha S, Séguin B.

J Exp Clin Cancer Res. 2013 Oct 11;32:74. doi: 10.1186/1756-9966-32-74.

11.

Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.

Darwish M, Kirby M, Robertson P Jr, Tracewell W, Xie F.

Clin Drug Investig. 2010;30(6):365-73. doi: 10.2165/11533360-000000000-00000.

PMID:
20441245
12.

Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B(1) pharmacokinetics in human volunteers.

Jubert C, Mata J, Bench G, Dashwood R, Pereira C, Tracewell W, Turteltaub K, Williams D, Bailey G.

Cancer Prev Res (Phila). 2009 Dec;2(12):1015-22. doi: 10.1158/1940-6207.CAPR-09-0099. Epub 2009 Dec 1.

13.

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.

Sweeney CJ, Takimoto C, Wood L, Porter JM, Tracewell WG, Darwish M, D'Andrea DM, Remick SC.

Cancer Chemother Pharmacol. 2010 Jul;66(2):345-56. doi: 10.1007/s00280-009-1169-4. Epub 2009 Nov 13.

PMID:
19911123
14.

Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects.

Darwish M, Kirby M, Jiang JG, Tracewell W, Robertson P Jr.

Clin Drug Investig. 2008;28(1):1-7.

PMID:
18081355
15.

Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study.

Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG.

Clin Drug Investig. 2007;27(9):605-11.

PMID:
17705569
16.

Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate.

Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG.

J Clin Pharmacol. 2007 Mar;47(3):343-50.

PMID:
17322146
18.

Clinical pharmacokinetics of thalidomide.

Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL.

Clin Pharmacokinet. 2004;43(5):311-27. Review.

PMID:
15080764
19.

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.

Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW.

Chest. 2002 Jul;122(1):219-26. Review.

PMID:
12114362
20.

Effect of colesevelam on lovastatin pharmacokinetics.

Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK.

Ann Pharmacother. 2002 Mar;36(3):392-7.

PMID:
11895049
21.

Thalidomide dose proportionality assessment following single doses to healthy subjects.

Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, Thomas SD.

J Clin Pharmacol. 2001 Jun;41(6):662-7.

PMID:
11402635
22.

Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women.

Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, Thomas SD.

Biopharm Drug Dispos. 2000 Jan;21(1):33-40.

PMID:
11038436
23.

Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoietic activities in swine.

Mata JE, Jackson JD, Joshi SS, Tracewell WG, Pirruccello SJ, Murphy BJ, Bishop MR, Iversen PL.

J Hematother Stem Cell Res. 2000 Apr;9(2):205-14.

PMID:
10813533
24.

Bioequivalence of a new strength tacrolimus capsule under development.

Bekersky I, Dressler D, Boswell GW, Fergen B, Tracewell W, Mekki Q.

Transplant Proc. 1998 Jun;30(4):1457-9. No abstract available.

PMID:
9636591
25.

Pharmacokinetics and pharmacodynamics of hydroxyurea.

Gwilt PR, Tracewell WG.

Clin Pharmacokinet. 1998 May;34(5):347-58. Review.

PMID:
9592619
26.

Population pharmacokinetics of glyburide in patients with well-controlled diabetes.

Tracewell WG, Stalker DJ, Maloley PA, Gallagher TF, Gwilt PR.

Pharmacotherapy. 1998 Jan-Feb;18(1):51-6.

PMID:
9469681
27.

In vivo modulation of the rat cytochrome P450 1A1 by double-stranded phosphorothioate oligodeoxynucleotides.

Tracewell W, Desjardins J, Iversen P.

Toxicol Appl Pharmacol. 1995 Dec;135(2):179-84.

PMID:
8545825
28.

Population pharmacokinetics of hydroxyurea in cancer patients.

Tracewell WG, Trump DL, Vaughan WP, Smith DC, Gwilt PR.

Cancer Chemother Pharmacol. 1995;35(5):417-22.

PMID:
7850924
29.

Nonlinear disposition of hydroxyurea.

Tracewell WG, Vaughan WP, Gwilt PR.

J Pharm Sci. 1994 Jul;83(7):1060-1. No abstract available.

PMID:
7965665
31.

The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.

Gwilt PR, Nahhas RR, Tracewell WG.

Clin Pharmacokinet. 1991 Jun;20(6):477-90. Review.

PMID:
2044331

Supplemental Content

Loading ...
Support Center